oral formulation of cannabis-derived cannabidiol, or CBD, intended to treat severe forms of childhood epilepsy. (GW Pharmaceuticals also manufactures Sativex, a mouth spray used for treatment of spasticity caused by multiple sclerosis; it includes THC and CBD derived from cannabis. Sativex was first approv

treat severe forms of childhood epilepsy. Human clinical trials have been conducted with both drugs, and although an NDA has not been sub- mitted for Sativex, an NDA for Epidiolex was submitted to the FDA in October 2017. If approved by the FDA, Epidiolex would be the first FDA-approved pharmaceutical deri

edical claims must obtain authorization from the Medicines and Healthcare Regulatory Agency (MHRA). Currently, licensed medical cannabis products are Sativex, Dronabinol and Nabilone. Epidiolex, medical grade pure CBD produced by British pharmaceutical company, GW Pharmaceuticals, is undergoing the licensi